Arrowhead Pharmaceuticals (ARWR) Reports Q4 Loss of $1.34
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Join SI Premium – FREE
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q4 EPS of ($1.34), versus ($1.60) reported last year. Revenue for the quarter came in at $158.33 thousand versus the consensus estimate of $382 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Broadcom credit risk measures rise amid AI financing deals
- MetLife (MET) PT Raised to $106 at Evercore ISI
- X Financial (XYF) Tops Q2 EPS by 438c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
